{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT02631577",
      "orgStudyIdInfo": {
        "id": "BO29562"
      },
      "secondaryIdInfos": [
        {
          "id": "2015-002467-42",
          "type": "EUDRACT_NUMBER"
        }
      ],
      "organization": {
        "fullName": "Hoffmann-La Roche",
        "class": "INDUSTRY"
      },
      "briefTitle": "A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma",
      "officialTitle": "A Phase Ib/II Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma"
    },
    "statusModule": {
      "statusVerifiedDate": "2022-04",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2015-12-31",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2018-10-23",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2020-10-07",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2015-12-14",
      "studyFirstSubmitQcDate": "2015-12-14",
      "studyFirstPostDateStruct": {
        "date": "2015-12-16",
        "type": "ESTIMATED"
      },
      "resultsFirstSubmitDate": "2019-10-15",
      "resultsFirstSubmitQcDate": "2019-12-12",
      "resultsFirstPostDateStruct": {
        "date": "2019-12-30",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2022-04-11",
      "lastUpdatePostDateStruct": {
        "date": "2022-04-13",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Hoffmann-La Roche",
        "class": "INDUSTRY"
      }
    },
    "descriptionModule": {
      "briefSummary": "This study will evaluate the safety, efficacy, pharmacokinetics and immunogenicity of induction treatment consisting of atezolizumab in combination with obinutuzumab plus lenalidomide in patients with relapsed or refractory follicular lymphoma (FL), followed by maintenance treatment with atezolizumab plus obinutzumab plus lenalidomide in patients who achieve a complete response (CR), a partial response (PR), or stable disease at end of induction."
    },
    "conditionsModule": {
      "conditions": [
        "Lymphoma, Follicular"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "designInfo": {
        "allocation": "NON_RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 38,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Atezolizumab-G-lena 15mg",
          "type": "EXPERIMENTAL",
          "description": "Participants were administered obinutuzumab, Atezolizumab, and 15 mg of Lenalidomide.",
          "interventionNames": [
            "Drug: Atezolizumab (MPDL3280A) [TECENTRIQ]",
            "Drug: Lenalidomide",
            "Drug: Obinutuzumab"
          ]
        },
        {
          "label": "Atezolizumab-G-lena 20mg",
          "type": "EXPERIMENTAL",
          "description": "Participants were administered obinutuzumab, Atezolizumab, and 20 mg of Lenalidomide.",
          "interventionNames": [
            "Drug: Atezolizumab (MPDL3280A) [TECENTRIQ]",
            "Drug: Lenalidomide",
            "Drug: Obinutuzumab"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Atezolizumab (MPDL3280A) [TECENTRIQ]",
          "description": "Atezolizumab will be administered at a flat dose of 840 mg on Days 1 and 15 of Cycles 2 to 6, given in 28-day cycles as induction treatment and 840 mg on Days 1 and 2 of each month, given as maintenance treatment.",
          "armGroupLabels": [
            "Atezolizumab-G-lena 15mg",
            "Atezolizumab-G-lena 20mg"
          ]
        },
        {
          "type": "DRUG",
          "name": "Lenalidomide",
          "description": "Lenalidomide will be administered orally once daily on Days 1 to 21 of Cycles 1 to 6 (28-day cycles) during induction treatment and on Days 1 to 21 of each month during maintenance treatment. Lenalidomide will be administered at a dose of 15 or 20 mg (dose may be de-escalated to 10 mg) during induction treatment and at 10 mg during maintenance treatment. During the expansion phase, lenalidomide will be administered at the RP2D during induction treatment and at 10 mg during maintenance treatment.",
          "armGroupLabels": [
            "Atezolizumab-G-lena 15mg",
            "Atezolizumab-G-lena 20mg"
          ]
        },
        {
          "type": "DRUG",
          "name": "Obinutuzumab",
          "description": "Obinutuzumab will be administered by intravenous infusion at an absolute (flat) dose of 1000 mg on Days 1, 8, and 15 of the first cycle and on Day 1 of each subsequent cycle during induction treatment, and on Day 1 of every other month (i.e., every 2 months) during maintenance treatment.",
          "armGroupLabels": [
            "Atezolizumab-G-lena 15mg",
            "Atezolizumab-G-lena 20mg"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Percentage of Participants Achieving Complete Response (CR) at End of Induction (EOI), as Determined by the Independent Review Committee (IRC) Using Modified Lugano 2014 Criteria",
          "description": "Complete response (CR) was evaluated through use of PET-CT scans, using the Modified Lugano 2014 criteria. Response was determined by the IRC.",
          "timeFrame": "6 months (up to clinical cut-off date (CCOD) of 23 October 2018)"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Percentage of Participants Achieving CR at EOI, as Determined by the Investigator Using Modified Lugano 2014 Criteria",
          "description": "CR was evaluated through use of PET-CT scans, using the Modified Lugano 2014 criteria. Response was determined by the Investigator.",
          "timeFrame": "6 months (up to CCOD of 23 October 2018)"
        },
        {
          "measure": "Percentage of Participants Achieving CR at EOI, as Determined by the IRC and Investigator Using Lugano 2014 Criteria",
          "description": "CR was evaluated through use of CT scans, using the Lugano 2014 criteria. Response was determined by the IRC and by the Investigator.",
          "timeFrame": "6 months (up to CCOD of 23 October 2018)"
        },
        {
          "measure": "Percentage of Participants With Objective Response (CR or PR) at EOI as Determined by the IRC and Investigator on the Basis of PET-CT Scans",
          "description": "Objective response was evaluated through use of PET-CT scans, using the Lugano 2014 or modified Lugano 2014 criteria. Response was determined by the IRC and by the Investigator.",
          "timeFrame": "6 months (up to CCOD of 23 October 2018)"
        },
        {
          "measure": "Percentage of Participants With Objective Response (CR or PR) at EOI as Determined by the IRC and Investigator on the Basis of CT Scans Alone",
          "description": "Objective response was evaluated through use of CT scans alone, using the Lugano 2014. Response was determined by the IRC and by the Investigator.",
          "timeFrame": "6 months (up to CCOD of 23 October 2018)"
        },
        {
          "measure": "Percentage of Participants With Best Response (CR or PR) During the Study as Determined by the Investigator on the Basis of CT Scans Alone",
          "description": "Best Response was evaluated through use of CT scans alone, using the Lugano 2014. Response was determined by the Investigator.",
          "timeFrame": "30 months"
        },
        {
          "measure": "Percentage of Participants With Adverse Events and Serious Adverse Events",
          "description": "An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.",
          "timeFrame": "Baseline up to approximately 59 months"
        },
        {
          "measure": "Number of Participants With Dose-limiting Toxicities (DLTs) During Cycle 2 of Study Treatment",
          "description": "Does limiting toxicity (DLT) is defined as any one of the following events occurring during Cycle 2 of treatment and assessed by the investigator as related to study treatment: - Adverse event of any grade that leads to a delay of more than 14 days at the start of the next treatment cycle; - Hematologic adverse events (neutropenia, thrombocytopenia); - Non-hematologic adverse event, except IRRs, diarrhea, nausea or vomiting",
          "timeFrame": "Day 1 - Day 28 of second cycle"
        },
        {
          "measure": "Serum Concentration of Obinutuzumab (mcg/mL)",
          "description": "The following abbreviations apply in the table: Ind C = Induction Cycle; D = Day; Maint M = Maintenance Month; TRTC = Study Drug Completion or Early Discontinuation; PK FU = Pharmacokinetics and Immunogenicity Follow-up; YR = Year",
          "timeFrame": "Baseline up to approximately 59 months"
        },
        {
          "measure": "Serum Concentration of Atezolizumab (mcg/mL)",
          "description": "The following abbreviations apply in the table: Ind C = Induction Cycle; D = Day; Maint M = Maintenance Month; TRTC = Study Drug Completion or Early Discontinuation; PK FU = Pharmacokinetics and Immunogenicity Follow-up; YR = Year",
          "timeFrame": "Baseline up to approximately 59 months"
        },
        {
          "measure": "Serum Concentration of Lenalidomide (ng/mL)",
          "description": "The following abbreviations apply in the table: Ind C = Induction Cycle; D = Day; HR = Hour",
          "timeFrame": "Baseline up to approximately 59 months"
        },
        {
          "measure": "Number of Participants Positive for Human Anti-human Antibodies (HAHA) to Obinutuzumab",
          "description": "The following abbreviations apply in the table: Ind C = Induction Cycle; D = Day; Maint M = Maintenance Month; TRTC = Study Drug Completion or Early Discontinuation; PK FU = Pharmacokinetics and Immunogenicity Follow-up; YR = Year. All baseline and post-baseline samples from participants were negative for HAHAs to obinutuzumab and the results are shown below.",
          "timeFrame": "Baseline up to approximately 59 months"
        },
        {
          "measure": "Number of Participants Positive for Anti-therapeutic Antibodies (ATAs) to Atezolizumab",
          "description": "The following abbreviations apply in the table: Ind C = Induction Cycle; D = Day; Maint M = Maintenance Month; TRTC = Study Drug Completion or Early Discontinuation; PK FU = Pharmacokinetics and Immunogenicity Follow-up; YR = Year. All baseline and post-baseline samples were negative for ATAs to atezolizumab and the results are shown below.",
          "timeFrame": "Baseline up to approximately 59 months"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2\n* Relapsed or refractory FL after treatment with at least one prior chemoimmunotherapy regimen that included an anti-CD20 monoclonal antibody and for which no other more appropriate treatment option exists as determined by the investigator\n* Histologically documented CD20-positive lymphoma as determined by the local laboratory\n* Fluorodeoxyglucose-avid lymphoma (i.e., PET-positive lymphoma)\n* At least one bi-dimensionally measurable lesion (\\>1.5 cm in its largest dimension by CT scan or magnetic resonance imaging \\[MRI\\])\n* Availability of a representative tumor specimen and the corresponding pathology report for retrospective central confirmation of the diagnosis of FL\n* Agreement to comply with all local requirements of the lenalidomide risk minimization plan\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use two adequate methods of contraception, including at least one method with a failure rate of \\<1% per year, for at least 28 days prior to Day 1 of Cycle 1, during the treatment period (including periods of treatment interruption), and for at least 18 months after the last dose of study treatment\n* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm for at least 3 months after the last dose of study treatment\n\nExclusion Criteria:\n\n* Grade 3b follicular lymphoma\n* History of transformation of indolent disease to diffuse large B-cell lymphoma (DLBCL)\n* Known CD20-negative status at relapse or progression\n* Central nervous system lymphoma or leptomeningeal infiltration\n* Prior allogeneic stem-cell transplantation (SCT)\n* Completion of autologous SCT within 100 days prior to Day (D) 1 of Cycle (C) 1\n* Prior standard or investigational anti-cancer therapy as specified in protocol\n* History of resistance to lenalidomide or response duration of \\<1 year\n* Treatment with systemic immunosuppressive medications\n* History of solid organ transplantation\n* Clinically significant toxicity from prior therapy that has not resolved to Grade \\<=2 (according to the National Cancer Institute Common Terminology Criteria for Adverse Events \\[NCI CTCAE\\], v4.0) prior to Day 1 of Cycle 1\n* History of erythema multiforme, Grade \\>= 3 rash, or blistering following prior treatment with immunomodulatory derivatives such as thalidomide and lenalidomide\n* Active bacterial, viral, fungal, or other infection\n* Positive for hepatitis B surface antigen (HBsAg), total hepatitis B core antibody (HBcAb), or hepatitis C virus (HCV) antibody at screening\n* Known history of HIV positive status\n* History of progressive multifocal leukoencephalopathy\n* History of autoimmune disease\n* Contraindication to treatment for TE prophylaxis\n* Grade \\<= 2 neuropathy\n* History of other malignancy that could affect compliance with the protocol or interpretation of results\n* Evidence of any significant, uncontrolled concomitant disease\n* Inadequate hematologic function (unless due to underlying lymphoma)\n* Abnormal laboratory values (unless due to underlying lymphoma)\n* Pregnant or lactating or intending to become pregnant during the study",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Clinical Trials",
          "affiliation": "Hoffmann-La Roche",
          "role": "STUDY_DIRECTOR"
        }
      ],
      "locations": [
        {
          "facility": "University of Alabama at Birmingham",
          "city": "Birmingham",
          "state": "Alabama",
          "zip": "35294",
          "country": "United States",
          "geoPoint": {
            "lat": 33.52066,
            "lon": -86.80249
          }
        },
        {
          "facility": "University Miami",
          "city": "Miami",
          "state": "Florida",
          "zip": "33136",
          "country": "United States",
          "geoPoint": {
            "lat": 25.77427,
            "lon": -80.19366
          }
        },
        {
          "facility": "Norton Medical Plaza II",
          "city": "Louisville",
          "state": "Kentucky",
          "zip": "40207",
          "country": "United States",
          "geoPoint": {
            "lat": 38.25424,
            "lon": -85.75941
          }
        },
        {
          "facility": "Memorial Sloan-Kettering Cancer Center; Hematology/Oncology",
          "city": "New York",
          "state": "New York",
          "zip": "10065",
          "country": "United States",
          "geoPoint": {
            "lat": 40.71427,
            "lon": -74.00597
          }
        },
        {
          "facility": "Levine Cancer Institute",
          "city": "Charlotte",
          "state": "North Carolina",
          "zip": "28204",
          "country": "United States",
          "geoPoint": {
            "lat": 35.22709,
            "lon": -80.84313
          }
        },
        {
          "facility": "Chu Toulouse",
          "city": "Bron",
          "zip": "69500",
          "country": "France",
          "geoPoint": {
            "lat": 45.73865,
            "lon": 4.91303
          }
        },
        {
          "facility": "Hopital Henri Mondor; 51 Av Mal Lattre De Tassigny",
          "city": "Créteil",
          "zip": "94010",
          "country": "France",
          "geoPoint": {
            "lat": 48.79266,
            "lon": 2.46569
          }
        },
        {
          "facility": "Hopital du Bocage",
          "city": "Dijon",
          "zip": "21034",
          "country": "France",
          "geoPoint": {
            "lat": 47.31344,
            "lon": 5.01391
          }
        },
        {
          "facility": "Centre Jean Bernard",
          "city": "Le Mans",
          "zip": "72015",
          "country": "France",
          "geoPoint": {
            "lat": 48.0021,
            "lon": 0.20251
          }
        },
        {
          "facility": "Centre Hospitalier Le Mans",
          "city": "Le Mans",
          "zip": "72037",
          "country": "France",
          "geoPoint": {
            "lat": 48.0021,
            "lon": 0.20251
          }
        },
        {
          "facility": "CHRU de Lille - Hopital Claude Huriez",
          "city": "Lille",
          "zip": "59037",
          "country": "France",
          "geoPoint": {
            "lat": 50.63391,
            "lon": 3.05512
          }
        },
        {
          "facility": "CHU Montpellier - Saint ELOI",
          "city": "Montpellier",
          "zip": "34295",
          "country": "France",
          "geoPoint": {
            "lat": 43.61093,
            "lon": 3.87635
          }
        },
        {
          "facility": "CHU - Hôtel Dieu hematolgie clinique",
          "city": "Nantes",
          "zip": "44093",
          "country": "France",
          "geoPoint": {
            "lat": 47.21725,
            "lon": -1.55336
          }
        },
        {
          "facility": "Centre Hospitalier Lyon Sud; Hematolgie",
          "city": "Pierre-Bénite",
          "zip": "69495",
          "country": "France",
          "geoPoint": {
            "lat": 45.70359,
            "lon": 4.82424
          }
        },
        {
          "facility": "CHU de Rennes - Hopital de Pontchaillo",
          "city": "Rennes",
          "zip": "35033",
          "country": "France",
          "geoPoint": {
            "lat": 48.11109,
            "lon": -1.67431
          }
        },
        {
          "facility": "Centre Henri Becquerel",
          "city": "Rouen",
          "zip": "76038",
          "country": "France",
          "geoPoint": {
            "lat": 49.44313,
            "lon": 1.09932
          }
        }
      ]
    }
  },
  "resultsSection": {
    "participantFlowModule": {
      "preAssignmentDetails": "All participants received daily low-dose aspirin (81-100 mg) during lenalidomide treatment and until 28 days after the last dose of lenalidomide. Participants who are unable to tolerate aspirin, who have a history of thromboembolism (TE), and who are at high risk of TE, received warfarin or low-molecular-weight heparin (LMWH).",
      "recruitmentDetails": "The study was conducted at 14 sites in France (9) and USA (5).",
      "groups": [
        {
          "id": "FG000",
          "title": "Atezolizumab-G-lena 15mg",
          "description": "Participants were administered obinutuzumab, atezolizumab, and 15 mg of lenalidomide"
        },
        {
          "id": "FG001",
          "title": "Atezolizumab-G-lena 20mg",
          "description": "Participants were administered obinutuzumab, atezolizumab, and 20 mg of lenalidomide."
        }
      ],
      "periods": [
        {
          "title": "Overall Study",
          "milestones": [
            {
              "type": "STARTED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "4"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "34"
                }
              ]
            },
            {
              "type": "COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "3"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "24"
                }
              ]
            },
            {
              "type": "NOT COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "10"
                }
              ]
            }
          ],
          "dropWithdraws": [
            {
              "type": "Death",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "7"
                }
              ]
            },
            {
              "type": "Withdrawal by Subject",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "3"
                }
              ]
            }
          ]
        }
      ]
    },
    "baselineCharacteristicsModule": {
      "groups": [
        {
          "id": "BG000",
          "title": "Atezolizumab-G-lena 15mg",
          "description": "Participants were administered obinutuzumab, atezolizumab, and 15 mg of lenalidomide"
        },
        {
          "id": "BG001",
          "title": "Atezolizumab-G-lena 20mg",
          "description": "Participants were administered obinutuzumab, atezolizumab, and 20 mg of lenalidomide."
        },
        {
          "id": "BG002",
          "title": "Total",
          "description": "Total of all reporting groups"
        }
      ],
      "denoms": [
        {
          "units": "Participants",
          "counts": [
            {
              "groupId": "BG000",
              "value": "4"
            },
            {
              "groupId": "BG001",
              "value": "34"
            },
            {
              "groupId": "BG002",
              "value": "38"
            }
          ]
        }
      ],
      "measures": [
        {
          "title": "Age, Continuous",
          "paramType": "MEAN",
          "dispersionType": "STANDARD_DEVIATION",
          "unitOfMeasure": "Years",
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "56.5",
                      "spread": "9.1"
                    },
                    {
                      "groupId": "BG001",
                      "value": "60.4",
                      "spread": "9.7"
                    },
                    {
                      "groupId": "BG002",
                      "value": "60.0",
                      "spread": "9.6"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Sex: Female, Male",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "Female",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "1"
                    },
                    {
                      "groupId": "BG001",
                      "value": "18"
                    },
                    {
                      "groupId": "BG002",
                      "value": "19"
                    }
                  ]
                },
                {
                  "title": "Male",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "3"
                    },
                    {
                      "groupId": "BG001",
                      "value": "16"
                    },
                    {
                      "groupId": "BG002",
                      "value": "19"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Race/Ethnicity, Customized",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "Hispanic or Latino",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "1"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "1"
                    }
                  ]
                },
                {
                  "title": "Not Hispanic or Latino",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "3"
                    },
                    {
                      "groupId": "BG001",
                      "value": "13"
                    },
                    {
                      "groupId": "BG002",
                      "value": "16"
                    }
                  ]
                },
                {
                  "title": "Not Stated",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "12"
                    },
                    {
                      "groupId": "BG002",
                      "value": "12"
                    }
                  ]
                },
                {
                  "title": "Unknown",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "9"
                    },
                    {
                      "groupId": "BG002",
                      "value": "9"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Race/Ethnicity, Customized",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "Unknown",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "20"
                    },
                    {
                      "groupId": "BG002",
                      "value": "20"
                    }
                  ]
                },
                {
                  "title": "White",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "4"
                    },
                    {
                      "groupId": "BG001",
                      "value": "14"
                    },
                    {
                      "groupId": "BG002",
                      "value": "18"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "outcomeMeasuresModule": {
      "outcomeMeasures": [
        {
          "type": "PRIMARY",
          "title": "Percentage of Participants Achieving Complete Response (CR) at End of Induction (EOI), as Determined by the Independent Review Committee (IRC) Using Modified Lugano 2014 Criteria",
          "description": "Complete response (CR) was evaluated through use of PET-CT scans, using the Modified Lugano 2014 criteria. Response was determined by the IRC.",
          "populationDescription": "As no DLTs were observed, the dose of 20 mg lenalidomide was confirmed as the recommended Phase II dose (RP2D) for lenalidomide. Only participants who received lenalidomide induction at the 20 mg RP2D were included in the Efficacy Evaluable population, hence participants in the Atezo-G-L 15 mg arm were not included in the efficacy analysis.",
          "reportingStatus": "POSTED",
          "paramType": "NUMBER",
          "dispersionType": "90% Confidence Interval",
          "unitOfMeasure": "Percentage of Participants",
          "timeFrame": "6 months (up to clinical cut-off date (CCOD) of 23 October 2018)",
          "groups": [
            {
              "id": "OG000",
              "title": "Atezolizumab-G-lena 15mg",
              "description": "Participants were administered obinutuzumab, atezolizumab, and 15 mg of lenalidomide."
            },
            {
              "id": "OG001",
              "title": "Atezolizumab-G-lena 20mg",
              "description": "Participants were administered obinutuzumab, atezolizumab, and 20 mg of lenalidomide."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "0"
                },
                {
                  "groupId": "OG001",
                  "value": "32"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG001",
                      "value": "71.9",
                      "lowerLimit": "56.06",
                      "upperLimit": "84.47"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Percentage of Participants Achieving CR at EOI, as Determined by the Investigator Using Modified Lugano 2014 Criteria",
          "description": "CR was evaluated through use of PET-CT scans, using the Modified Lugano 2014 criteria. Response was determined by the Investigator.",
          "populationDescription": "As no DLTs were observed, the dose of 20 mg lenalidomide was confirmed as the recommended Phase II dose (RP2D) for lenalidomide. Only participants who received lenalidomide induction at the 20 mg RP2D were included in the Efficacy Evaluable population, hence participants in the Atezo-G-L 15 mg arm were not included in the efficacy analysis.",
          "reportingStatus": "POSTED",
          "paramType": "NUMBER",
          "dispersionType": "90% Confidence Interval",
          "unitOfMeasure": "Percentage of Participants",
          "timeFrame": "6 months (up to CCOD of 23 October 2018)",
          "groups": [
            {
              "id": "OG000",
              "title": "Atezolizumab-G-lena 15mg",
              "description": "Participants were administered obinutuzumab, atezolizumab, and 15 mg of lenalidomide."
            },
            {
              "id": "OG001",
              "title": "Atezolizumab-G-lena 20mg",
              "description": "Participants were administered obinutuzumab, atezolizumab, and 20 mg of lenalidomide."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "0"
                },
                {
                  "groupId": "OG001",
                  "value": "32"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG001",
                      "value": "75",
                      "lowerLimit": "59.39",
                      "upperLimit": "86.91"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Percentage of Participants Achieving CR at EOI, as Determined by the IRC and Investigator Using Lugano 2014 Criteria",
          "description": "CR was evaluated through use of CT scans, using the Lugano 2014 criteria. Response was determined by the IRC and by the Investigator.",
          "populationDescription": "As no DLTs were observed, the dose of 20 mg lenalidomide was confirmed as the recommended Phase II dose (RP2D) for lenalidomide. Only participants who received lenalidomide induction at the 20 mg RP2D were included in the Efficacy Evaluable population, hence participants in the Atezo-G-L 15 mg arm were not included in the efficacy analysis.",
          "reportingStatus": "POSTED",
          "paramType": "NUMBER",
          "dispersionType": "90% Confidence Interval",
          "unitOfMeasure": "Percentage of Participants",
          "timeFrame": "6 months (up to CCOD of 23 October 2018)",
          "groups": [
            {
              "id": "OG000",
              "title": "Atezolizumab-G-lena 15mg",
              "description": "Participants were administered obinutuzumab, atezolizumab, and 15 mg of lenalidomide."
            },
            {
              "id": "OG001",
              "title": "Atezolizumab-G-lena 20mg",
              "description": "Participants were administered obinutuzumab, atezolizumab, and 20 mg of lenalidomide."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "0"
                },
                {
                  "groupId": "OG001",
                  "value": "32"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Determined by the IRC with CT or MRI",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG001",
                      "value": "31.3",
                      "lowerLimit": "18.04",
                      "upperLimit": "47.21"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Determined by Investigator with CT or MRI",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG001",
                      "value": "50",
                      "lowerLimit": "34.41",
                      "upperLimit": "65.59"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Percentage of Participants With Objective Response (CR or PR) at EOI as Determined by the IRC and Investigator on the Basis of PET-CT Scans",
          "description": "Objective response was evaluated through use of PET-CT scans, using the Lugano 2014 or modified Lugano 2014 criteria. Response was determined by the IRC and by the Investigator.",
          "populationDescription": "As no DLTs were observed, the dose of 20 mg lenalidomide was confirmed as the recommended Phase II dose (RP2D) for lenalidomide. Only participants who received lenalidomide induction at the 20 mg RP2D were included in the Efficacy Evaluable population, hence participants in the Atezo-G-L 15 mg arm were not included in the efficacy analysis.",
          "reportingStatus": "POSTED",
          "paramType": "NUMBER",
          "dispersionType": "90% Confidence Interval",
          "unitOfMeasure": "Percentage of Participants",
          "timeFrame": "6 months (up to CCOD of 23 October 2018)",
          "groups": [
            {
              "id": "OG000",
              "title": "Atezolizumab-G-lena 15mg",
              "description": "Participants were administered obinutuzumab, atezolizumab, and 15 mg of lenalidomide."
            },
            {
              "id": "OG001",
              "title": "Atezolizumab-G-lena 20mg",
              "description": "Participants were administered obinutuzumab, atezolizumab, and 20 mg of lenalidomide."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "0"
                },
                {
                  "groupId": "OG001",
                  "value": "32"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Determined by IRC, based on Lugano 2014 - PET",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG001",
                      "value": "81.3",
                      "lowerLimit": "66.31",
                      "upperLimit": "91.50"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Determined by Inv., based on Lugano 2014 - PET",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG001",
                      "value": "84.4",
                      "lowerLimit": "69.92",
                      "upperLimit": "93.63"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Determined by IRC, Modified Lugano 2014 - PET-CT",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG001",
                      "value": "78.1",
                      "lowerLimit": "62.81",
                      "upperLimit": "89.26"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Determined by Inv, Modified Lugano 2014 - PET-CT",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG001",
                      "value": "84.4",
                      "lowerLimit": "69.92",
                      "upperLimit": "93.63"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Percentage of Participants With Objective Response (CR or PR) at EOI as Determined by the IRC and Investigator on the Basis of CT Scans Alone",
          "description": "Objective response was evaluated through use of CT scans alone, using the Lugano 2014. Response was determined by the IRC and by the Investigator.",
          "populationDescription": "As no DLTs were observed, the dose of 20 mg lenalidomide was confirmed as the recommended Phase II dose (RP2D) for lenalidomide. Only participants who received lenalidomide induction at the 20 mg RP2D were included in the Efficacy Evaluable population, hence participants in the Atezo-G-L 15 mg arm were not included in the efficacy analysis.",
          "reportingStatus": "POSTED",
          "paramType": "NUMBER",
          "dispersionType": "90% Confidence Interval",
          "unitOfMeasure": "Percentage of Participants",
          "timeFrame": "6 months (up to CCOD of 23 October 2018)",
          "groups": [
            {
              "id": "OG000",
              "title": "Atezolizumab-G-lena 15mg",
              "description": "Participants were administered obinutuzumab, atezolizumab, and 15 mg of lenalidomide."
            },
            {
              "id": "OG001",
              "title": "Atezolizumab-G-lena 20mg",
              "description": "Participants were administered obinutuzumab, atezolizumab, and 20 mg of lenalidomide."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "0"
                },
                {
                  "groupId": "OG001",
                  "value": "32"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Determined by IRC, based on Lugano 2014 - CT",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG001",
                      "value": "81.3",
                      "lowerLimit": "66.31",
                      "upperLimit": "91.50"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Determined by Inv., based on Lugano 2014 - CT",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG001",
                      "value": "87.5",
                      "lowerLimit": "73.64",
                      "upperLimit": "95.62"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Percentage of Participants With Best Response (CR or PR) During the Study as Determined by the Investigator on the Basis of CT Scans Alone",
          "description": "Best Response was evaluated through use of CT scans alone, using the Lugano 2014. Response was determined by the Investigator.",
          "populationDescription": "As no DLTs were observed, the dose of 20 mg lenalidomide was confirmed as the recommended Phase II dose (RP2D) for lenalidomide. Only participants who received lenalidomide induction at the 20 mg RP2D were included in the Efficacy Evaluable population, hence participants in the Atezo-G-L 15 mg arm were not included in the efficacy analysis.",
          "reportingStatus": "POSTED",
          "paramType": "NUMBER",
          "dispersionType": "90% Confidence Interval",
          "unitOfMeasure": "Percentage",
          "timeFrame": "30 months",
          "groups": [
            {
              "id": "OG000",
              "title": "Atezolizumab-G-lena 15mg",
              "description": "Participants were administered obinutuzumab, atezolizumab, and 15 mg of lenalidomide."
            },
            {
              "id": "OG001",
              "title": "Atezolizumab-G-lena 20mg",
              "description": "Participants were administered obinutuzumab, atezolizumab, and 20 mg of lenalidomide."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "0"
                },
                {
                  "groupId": "OG001",
                  "value": "32"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Best Response (CR,PR)",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG001",
                      "value": "87.5",
                      "lowerLimit": "73.64",
                      "upperLimit": "95.62"
                    }
                  ]
                }
              ]
            },
            {
              "title": "CR",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG001",
                      "value": "68.8",
                      "lowerLimit": "52.79",
                      "upperLimit": "81.96"
                    }
                  ]
                }
              ]
            },
            {
              "title": "PR",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG001",
                      "value": "18.8",
                      "lowerLimit": "8.50",
                      "upperLimit": "33.69"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Percentage of Participants With Adverse Events and Serious Adverse Events",
          "description": "An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.",
          "populationDescription": "The Safety Evaluable Population included participants who received at least one dose of any study treatment.",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "Baseline up to approximately 59 months",
          "groups": [
            {
              "id": "OG000",
              "title": "Atezolizumab-G-lena 15mg",
              "description": "Participants were administered obinutuzumab, atezolizumab, and 15 mg of lenalidomide."
            },
            {
              "id": "OG001",
              "title": "Atezolizumab-G-lena 20mg",
              "description": "Participants were administered obinutuzumab, atezolizumab, and 20 mg of lenalidomide."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "4"
                },
                {
                  "groupId": "OG001",
                  "value": "34"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Adverse Events",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "4"
                    },
                    {
                      "groupId": "OG001",
                      "value": "34"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Serious Adverse Events",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "2"
                    },
                    {
                      "groupId": "OG001",
                      "value": "16"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Number of Participants With Dose-limiting Toxicities (DLTs) During Cycle 2 of Study Treatment",
          "description": "Does limiting toxicity (DLT) is defined as any one of the following events occurring during Cycle 2 of treatment and assessed by the investigator as related to study treatment: - Adverse event of any grade that leads to a delay of more than 14 days at the start of the next treatment cycle; - Hematologic adverse events (neutropenia, thrombocytopenia); - Non-hematologic adverse event, except IRRs, diarrhea, nausea or vomiting",
          "populationDescription": "The Safety Evaluable Population included participants who received at least one dose of any study treatment.",
          "reportingStatus": "POSTED",
          "paramType": "NUMBER",
          "unitOfMeasure": "Number of Participants",
          "timeFrame": "Day 1 - Day 28 of second cycle",
          "groups": [
            {
              "id": "OG000",
              "title": "Atezolizumab-G-lena 15mg",
              "description": "Participants were administered obinutuzumab, atezolizumab, and 15 mg of lenalidomide."
            },
            {
              "id": "OG001",
              "title": "Atezolizumab-G-lena 20mg",
              "description": "Participants were administered obinutuzumab, atezolizumab, and 20 mg of lenalidomide."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "4"
                },
                {
                  "groupId": "OG001",
                  "value": "34"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "0"
                    },
                    {
                      "groupId": "OG001",
                      "value": "0"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Serum Concentration of Obinutuzumab (mcg/mL)",
          "description": "The following abbreviations apply in the table: Ind C = Induction Cycle; D = Day; Maint M = Maintenance Month; TRTC = Study Drug Completion or Early Discontinuation; PK FU = Pharmacokinetics and Immunogenicity Follow-up; YR = Year",
          "populationDescription": "The Safety Evaluable Population included participants who received at least one dose of any study treatment.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "mcg/mL",
          "timeFrame": "Baseline up to approximately 59 months",
          "groups": [
            {
              "id": "OG000",
              "title": "Atezolizumab-G-lena 15mg",
              "description": "Participants were administered obinutuzumab, atezolizumab, and 15 mg of lenalidomide."
            },
            {
              "id": "OG001",
              "title": "Atezolizumab-G-lena 20mg",
              "description": "Participants were administered obinutuzumab, atezolizumab, and 20 mg of lenalidomide."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "4"
                },
                {
                  "groupId": "OG001",
                  "value": "34"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Ind C1 D1 - Predose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "0"
                    },
                    {
                      "groupId": "OG001",
                      "value": "2"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG001",
                      "value": "0.634",
                      "spread": "0.857"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ind C1 D1 - 30 min. Postdose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "4"
                    },
                    {
                      "groupId": "OG001",
                      "value": "30"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "364",
                      "spread": "45.9"
                    },
                    {
                      "groupId": "OG001",
                      "value": "375",
                      "spread": "163"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ind C2 D1 - Predose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "4"
                    },
                    {
                      "groupId": "OG001",
                      "value": "32"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "288",
                      "spread": "84.2"
                    },
                    {
                      "groupId": "OG001",
                      "value": "392",
                      "spread": "164"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ind C2 D1 - 30 min. Postdose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "4"
                    },
                    {
                      "groupId": "OG001",
                      "value": "31"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "606",
                      "spread": "62.4"
                    },
                    {
                      "groupId": "OG001",
                      "value": "753",
                      "spread": "225"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ind C4 D1 - Predose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "25"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "175",
                      "spread": "38.5"
                    },
                    {
                      "groupId": "OG001",
                      "value": "301",
                      "spread": "150"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ind C4 D1 - 30 min. Postdose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "23"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "509",
                      "spread": "47.0"
                    },
                    {
                      "groupId": "OG001",
                      "value": "657",
                      "spread": "198"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ind C6 D1 - Predose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "20"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "230",
                      "spread": "12.3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "272",
                      "spread": "106"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ind C6 D1 - 30 min. Postdose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "20"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "503",
                      "spread": "25.5"
                    },
                    {
                      "groupId": "OG001",
                      "value": "652",
                      "spread": "177"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Maint M1 - Predose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "20"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "114",
                      "spread": "16.7"
                    },
                    {
                      "groupId": "OG001",
                      "value": "201",
                      "spread": "104"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Maint M7 - Predose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "2"
                    },
                    {
                      "groupId": "OG001",
                      "value": "17"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "66.1",
                      "spread": "20.4"
                    },
                    {
                      "groupId": "OG001",
                      "value": "112",
                      "spread": "52.1"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Maint M13 - Predose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    },
                    {
                      "groupId": "OG001",
                      "value": "18"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "77.9",
                      "spread": "NA",
                      "comment": "The standard deviation couldn't be calculated from one participant."
                    },
                    {
                      "groupId": "OG001",
                      "value": "104",
                      "spread": "62.9"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Maint M19 - Predose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "2"
                    },
                    {
                      "groupId": "OG001",
                      "value": "12"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "94.0",
                      "spread": "24.0"
                    },
                    {
                      "groupId": "OG001",
                      "value": "111",
                      "spread": "49.8"
                    }
                  ]
                }
              ]
            },
            {
              "title": "TRTC",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "0"
                    },
                    {
                      "groupId": "OG001",
                      "value": "12"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG001",
                      "value": "148",
                      "spread": "103"
                    }
                  ]
                }
              ]
            },
            {
              "title": "OD120FU",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    },
                    {
                      "groupId": "OG001",
                      "value": "10"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "23.3",
                      "spread": "NA",
                      "comment": "The standard deviation couldn't be calculated from one participant."
                    },
                    {
                      "groupId": "OG001",
                      "value": "46.2",
                      "spread": "38.6"
                    }
                  ]
                }
              ]
            },
            {
              "title": "O1YFU",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "2"
                    },
                    {
                      "groupId": "OG001",
                      "value": "4"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "46.9",
                      "spread": "66.2"
                    },
                    {
                      "groupId": "OG001",
                      "value": "57.9",
                      "spread": "115"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Serum Concentration of Atezolizumab (mcg/mL)",
          "description": "The following abbreviations apply in the table: Ind C = Induction Cycle; D = Day; Maint M = Maintenance Month; TRTC = Study Drug Completion or Early Discontinuation; PK FU = Pharmacokinetics and Immunogenicity Follow-up; YR = Year",
          "populationDescription": "The Safety Evaluable Population included participants who received at least one dose of any study treatment.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "micrograms per milliliter (mcg/mL)",
          "timeFrame": "Baseline up to approximately 59 months",
          "groups": [
            {
              "id": "OG000",
              "title": "Atezolizumab-G-lena 15mg",
              "description": "Participants were administered obinutuzumab, atezolizumab, and 15 mg of lenalidomide."
            },
            {
              "id": "OG001",
              "title": "Atezolizumab-G-lena 20mg",
              "description": "Participants were administered obinutuzumab, atezolizumab, and 20 mg of lenalidomide."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "4"
                },
                {
                  "groupId": "OG001",
                  "value": "34"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Ind C2 D1 - Predose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "0"
                    },
                    {
                      "groupId": "OG001",
                      "value": "1"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG001",
                      "value": "0.184",
                      "spread": "NA",
                      "comment": "The standard deviation couldn't be calculated from one participant."
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ind C2 D1 - 30 min. Postdose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "4"
                    },
                    {
                      "groupId": "OG001",
                      "value": "32"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "345",
                      "spread": "195"
                    },
                    {
                      "groupId": "OG001",
                      "value": "279",
                      "spread": "123"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ind C2 D15 - Predose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "32"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "73.8",
                      "spread": "6.47"
                    },
                    {
                      "groupId": "OG001",
                      "value": "90.0",
                      "spread": "33.8"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ind C4 D1 - Predose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "2"
                    },
                    {
                      "groupId": "OG001",
                      "value": "29"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "128",
                      "spread": "33.9"
                    },
                    {
                      "groupId": "OG001",
                      "value": "226",
                      "spread": "93.9"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ind C4 D1 - 30 min. Postdose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "2"
                    },
                    {
                      "groupId": "OG001",
                      "value": "27"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "340",
                      "spread": "38.2"
                    },
                    {
                      "groupId": "OG001",
                      "value": "477",
                      "spread": "126"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ind C6 D1 - Predose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "28"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "194",
                      "spread": "40.6"
                    },
                    {
                      "groupId": "OG001",
                      "value": "279",
                      "spread": "117"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Maint M1 - Predose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "27"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "79.0",
                      "spread": "67.6"
                    },
                    {
                      "groupId": "OG001",
                      "value": "172",
                      "spread": "76.5"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Maint M1 - Day 2, 30 min. Postdose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "23"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "653",
                      "spread": "106"
                    },
                    {
                      "groupId": "OG001",
                      "value": "666",
                      "spread": "185"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Maint M4 - Predose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "25"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "174",
                      "spread": "32.9"
                    },
                    {
                      "groupId": "OG001",
                      "value": "292",
                      "spread": "97.1"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Maint M7 - Predose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "2"
                    },
                    {
                      "groupId": "OG001",
                      "value": "20"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "209",
                      "spread": "12.7"
                    },
                    {
                      "groupId": "OG001",
                      "value": "322",
                      "spread": "109"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Maint M13 - Predose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    },
                    {
                      "groupId": "OG001",
                      "value": "19"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "203",
                      "spread": "NA",
                      "comment": "The standard deviation couldn't be calculated from one participant."
                    },
                    {
                      "groupId": "OG001",
                      "value": "309",
                      "spread": "140"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Maint M19 - Predose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    },
                    {
                      "groupId": "OG001",
                      "value": "11"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "351",
                      "spread": "NA",
                      "comment": "The standard deviation couldn't be calculated from one participant."
                    },
                    {
                      "groupId": "OG001",
                      "value": "327",
                      "spread": "140"
                    }
                  ]
                }
              ]
            },
            {
              "title": "TRTC",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "0"
                    },
                    {
                      "groupId": "OG001",
                      "value": "13"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG001",
                      "value": "116",
                      "spread": "81.9"
                    }
                  ]
                }
              ]
            },
            {
              "title": "PK FU 120D",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    },
                    {
                      "groupId": "OG001",
                      "value": "11"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "46.0",
                      "spread": "NA",
                      "comment": "The standard deviation couldn't be calculated from one participant."
                    },
                    {
                      "groupId": "OG001",
                      "value": "38.4",
                      "spread": "24.6"
                    }
                  ]
                }
              ]
            },
            {
              "title": "PK FU 1YR",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "0"
                    },
                    {
                      "groupId": "OG001",
                      "value": "0"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Serum Concentration of Lenalidomide (ng/mL)",
          "description": "The following abbreviations apply in the table: Ind C = Induction Cycle; D = Day; HR = Hour",
          "populationDescription": "The Safety Evaluable Population included participants who received at least one dose of any study treatment.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "nanograms/milliliter (ng/mL)",
          "timeFrame": "Baseline up to approximately 59 months",
          "groups": [
            {
              "id": "OG000",
              "title": "Atezolizumab-G-lena 15mg",
              "description": "Participants were administered obinutuzumab, atezolizumab, and 15 mg of lenalidomide."
            },
            {
              "id": "OG001",
              "title": "Atezolizumab-G-lena 20mg",
              "description": "Participants were administered obinutuzumab, atezolizumab, and 20 mg of lenalidomide."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "4"
                },
                {
                  "groupId": "OG001",
                  "value": "34"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Ind C1 D1 - Predose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "0"
                    },
                    {
                      "groupId": "OG001",
                      "value": "0"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ind C1 D15 - Predose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "4"
                    },
                    {
                      "groupId": "OG001",
                      "value": "17"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "12.6",
                      "spread": "14.3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "13.0",
                      "spread": "11.4"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ind C1 D15 - 2.0 hr. Postdose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "4"
                    },
                    {
                      "groupId": "OG001",
                      "value": "18"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "254",
                      "spread": "115"
                    },
                    {
                      "groupId": "OG001",
                      "value": "294",
                      "spread": "114"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ind C2 D15 - Predose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "21"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "3.57",
                      "spread": "3.25"
                    },
                    {
                      "groupId": "OG001",
                      "value": "15.0",
                      "spread": "13.0"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ind C2 D15 - 30 min. Postdose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "19"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "241",
                      "spread": "116"
                    },
                    {
                      "groupId": "OG001",
                      "value": "293",
                      "spread": "233"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ind C2 D15 -1.0 hr. Postdose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "20"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "224",
                      "spread": "43.1"
                    },
                    {
                      "groupId": "OG001",
                      "value": "354",
                      "spread": "120"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ind C2 D15 - 2.0 hr. Postdose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "19"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "146",
                      "spread": "41.9"
                    },
                    {
                      "groupId": "OG001",
                      "value": "262",
                      "spread": "82.1"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ind C2 D15 - 4.0 hr. Postdose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "20"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "95.8",
                      "spread": "18.3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "150",
                      "spread": "47.1"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ind C2 D15 - 8.0 hr. Postdose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "20"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "45.9",
                      "spread": "23.9"
                    },
                    {
                      "groupId": "OG001",
                      "value": "68.4",
                      "spread": "33.6"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ind C6 D15 - Predose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "12"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "5.72",
                      "spread": "3.73"
                    },
                    {
                      "groupId": "OG001",
                      "value": "9.17",
                      "spread": "6.87"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ind C6 D15 - 2.0 hr. Postdose",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "12"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "200",
                      "spread": "57.5"
                    },
                    {
                      "groupId": "OG001",
                      "value": "214",
                      "spread": "77.6"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Number of Participants Positive for Human Anti-human Antibodies (HAHA) to Obinutuzumab",
          "description": "The following abbreviations apply in the table: Ind C = Induction Cycle; D = Day; Maint M = Maintenance Month; TRTC = Study Drug Completion or Early Discontinuation; PK FU = Pharmacokinetics and Immunogenicity Follow-up; YR = Year. All baseline and post-baseline samples from participants were negative for HAHAs to obinutuzumab and the results are shown below.",
          "populationDescription": "The Safety Evaluable Population included participants who received at least one dose of any study treatment.",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "Baseline up to approximately 59 months",
          "groups": [
            {
              "id": "OG000",
              "title": "Atezolizumab-G-lena 15mg",
              "description": "Participants were administered obinutuzumab, atezolizumab, and 15 mg of lenalidomide."
            },
            {
              "id": "OG001",
              "title": "Atezolizumab-G-lena 20mg",
              "description": "Participants were administered obinutuzumab, atezolizumab, and 20 mg of lenalidomide."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "4"
                },
                {
                  "groupId": "OG001",
                  "value": "34"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Baseline - Negative",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "4"
                    },
                    {
                      "groupId": "OG001",
                      "value": "34"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "4"
                    },
                    {
                      "groupId": "OG001",
                      "value": "34"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ind C6 D1 - Negative",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "27"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "27"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Study drug completion or early discontinuation - Negative",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "0"
                    },
                    {
                      "groupId": "OG001",
                      "value": "15"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "0"
                    },
                    {
                      "groupId": "OG001",
                      "value": "15"
                    }
                  ]
                }
              ]
            },
            {
              "title": "OB, PK, IMMUNO FU 120D - Negative",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    },
                    {
                      "groupId": "OG001",
                      "value": "11"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    },
                    {
                      "groupId": "OG001",
                      "value": "11"
                    }
                  ]
                }
              ]
            },
            {
              "title": "OB, PK, IMMUNO FU 1YR - Negative",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "2"
                    },
                    {
                      "groupId": "OG001",
                      "value": "4"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "2"
                    },
                    {
                      "groupId": "OG001",
                      "value": "4"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Number of Participants Positive for Anti-therapeutic Antibodies (ATAs) to Atezolizumab",
          "description": "The following abbreviations apply in the table: Ind C = Induction Cycle; D = Day; Maint M = Maintenance Month; TRTC = Study Drug Completion or Early Discontinuation; PK FU = Pharmacokinetics and Immunogenicity Follow-up; YR = Year. All baseline and post-baseline samples were negative for ATAs to atezolizumab and the results are shown below.",
          "populationDescription": "The Safety Evaluable Population included participants who received at least one dose of any study treatment.",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "Baseline up to approximately 59 months",
          "groups": [
            {
              "id": "OG000",
              "title": "Atezolizumab-G-lena 15mg",
              "description": "Participants were administered obinutuzumab, atezolizumab, and 15 mg of lenalidomide."
            },
            {
              "id": "OG001",
              "title": "Atezolizumab-G-lena 20mg",
              "description": "Participants were administered obinutuzumab, atezolizumab, and 20 mg of lenalidomide."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "4"
                },
                {
                  "groupId": "OG001",
                  "value": "34"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Ind C2 D1 - Negative",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "4"
                    },
                    {
                      "groupId": "OG001",
                      "value": "31"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "4"
                    },
                    {
                      "groupId": "OG001",
                      "value": "31"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ind C2 D15 - Negative",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "2"
                    },
                    {
                      "groupId": "OG001",
                      "value": "32"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "2"
                    },
                    {
                      "groupId": "OG001",
                      "value": "32"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ind C4 D1 - Negative",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "29"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "29"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Ind C6 D1 - Negative",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "28"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "28"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Maint M1 - Negative",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "27"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "27"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Maint M4 - Negative",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "25"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "25"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Maint M7 - Negative",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "2"
                    },
                    {
                      "groupId": "OG001",
                      "value": "21"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "2"
                    },
                    {
                      "groupId": "OG001",
                      "value": "21"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Maint M13 - Negative",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    },
                    {
                      "groupId": "OG001",
                      "value": "20"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    },
                    {
                      "groupId": "OG001",
                      "value": "20"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Maint M19 - Negative",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "2"
                    },
                    {
                      "groupId": "OG001",
                      "value": "12"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "2"
                    },
                    {
                      "groupId": "OG001",
                      "value": "12"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Study drug completion or early discontinuation - Negative",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "2"
                    },
                    {
                      "groupId": "OG001",
                      "value": "15"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "2"
                    },
                    {
                      "groupId": "OG001",
                      "value": "15"
                    }
                  ]
                }
              ]
            },
            {
              "title": "ATEZO, PK, IMMUNO FU 120D - Negative",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    },
                    {
                      "groupId": "OG001",
                      "value": "11"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    },
                    {
                      "groupId": "OG001",
                      "value": "11"
                    }
                  ]
                }
              ]
            },
            {
              "title": "ATEZO, PK, IMMUNO FU 1YR - Negative",
              "denoms": [
                {
                  "units": "Participants",
                  "counts": [
                    {
                      "groupId": "OG000",
                      "value": "2"
                    },
                    {
                      "groupId": "OG001",
                      "value": "3"
                    }
                  ]
                }
              ],
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "2"
                    },
                    {
                      "groupId": "OG001",
                      "value": "3"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "adverseEventsModule": {
      "frequencyThreshold": "5",
      "timeFrame": "Baseline up to approximately 59 months",
      "description": "The safety population included all participants who received at least one treatment with study medication. The adverse event severity grading scale for the NCI CTCAE v4.0 was used.",
      "eventGroups": [
        {
          "id": "EG000",
          "title": "Atezolizumab-G-lena 15mg",
          "description": "Participants were administered obinutuzumab, atezolizumab, and 15 mg of lenalidomide",
          "deathsNumAffected": 1,
          "deathsNumAtRisk": 4,
          "seriousNumAffected": 2,
          "seriousNumAtRisk": 4,
          "otherNumAffected": 4,
          "otherNumAtRisk": 4
        },
        {
          "id": "EG001",
          "title": "Atezolizumab-G-lena 20mg",
          "description": "Participants were administered obinutuzumab, atezolizumab, and 20 mg of lenalidomide.",
          "deathsNumAffected": 7,
          "deathsNumAtRisk": 34,
          "seriousNumAffected": 16,
          "seriousNumAtRisk": 34,
          "otherNumAffected": 34,
          "otherNumAtRisk": 34
        }
      ],
      "seriousEvents": [
        {
          "term": "FEBRILE NEUTROPENIA",
          "organSystem": "Blood and lymphatic system disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 1,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "ABDOMINAL PAIN",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "ADMINISTRATION SITE EXTRAVASATION",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "EAR INFECTION",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "EPIDIDYMITIS",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "INFLUENZA",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "PNEUMONIA PARAINFLUENZAE VIRAL",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "INFUSION RELATED REACTION",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "DEHYDRATION",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "MENINGIOMA",
          "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "TUMOUR FLARE",
          "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "ISCHAEMIC STROKE",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "DYSPNOEA",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "DEEP VEIN THROMBOSIS",
          "organSystem": "Vascular disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "ORTHOSTATIC HYPOTENSION",
          "organSystem": "Vascular disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "CELLULITIS",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "PNEUMONIA",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "LUMBAR VERTEBRAL FRACTURE",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "ACUTE MYELOID LEUKAEMIA",
          "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "ATYPICAL FIBROXANTHOMA",
          "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "BASAL CELL CARCINOMA",
          "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "LUNG NEOPLASM MALIGNANT",
          "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "NEUROENDOCRINE CARCINOMA OF THE SKIN",
          "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "SARCOMATOID CARCINOMA",
          "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "LUNG DISORDER",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        }
      ],
      "otherEvents": [
        {
          "term": "ANAEMIA",
          "organSystem": "Blood and lymphatic system disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 6,
              "numAffected": 6,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "LEUKOPENIA",
          "organSystem": "Blood and lymphatic system disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "NEUTROPENIA",
          "organSystem": "Blood and lymphatic system disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 4,
              "numAffected": 3,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 43,
              "numAffected": 14,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "THROMBOCYTOPENIA",
          "organSystem": "Blood and lymphatic system disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 14,
              "numAffected": 9,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "TACHYCARDIA",
          "organSystem": "Cardiac disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "VERTIGO",
          "organSystem": "Ear and labyrinth disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "HYPERTHYROIDISM",
          "organSystem": "Endocrine disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 9,
              "numAffected": 7,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "HYPOTHYROIDISM",
          "organSystem": "Endocrine disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 6,
              "numAffected": 6,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "LACRIMATION INCREASED",
          "organSystem": "Eye disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "ABDOMINAL DISTENSION",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "ABDOMINAL PAIN",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 10,
              "numAffected": 8,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "ABDOMINAL PAIN UPPER",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 2,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 1,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "CONSTIPATION",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 5,
              "numAffected": 3,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 13,
              "numAffected": 12,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "DIARRHOEA",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 9,
              "numAffected": 3,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 42,
              "numAffected": 19,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "DYSPEPSIA",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 6,
              "numAffected": 3,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "DYSPHAGIA",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "HAEMATOCHEZIA",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "NAUSEA",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 4,
              "numAffected": 4,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 7,
              "numAffected": 4,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "RECTAL HAEMORRHAGE",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "STOMATITIS",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "VOMITING",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 8,
              "numAffected": 4,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 4,
              "numAffected": 3,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "ASTHENIA",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 20,
              "numAffected": 14,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "AXILLARY PAIN",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "FATIGUE",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 10,
              "numAffected": 8,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "INFLUENZA LIKE ILLNESS",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "NON-CARDIAC CHEST PAIN",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "OEDEMA PERIPHERAL",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 8,
              "numAffected": 5,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "PERIPHERAL SWELLING",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "PYREXIA",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 6,
              "numAffected": 5,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "XEROSIS",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "CHOLECYSTITIS",
          "organSystem": "Hepatobiliary disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "HEPATOCELLULAR INJURY",
          "organSystem": "Hepatobiliary disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 4,
              "numAffected": 3,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "BRONCHIOLITIS",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "BRONCHITIS",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 13,
              "numAffected": 10,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "CONJUNCTIVITIS",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "FUNGAL SKIN INFECTION",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "GASTROENTERITIS",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "HERPES ZOSTER",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "INFLUENZA",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 6,
              "numAffected": 6,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "NASOPHARYNGITIS",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 10,
              "numAffected": 6,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "PHARYNGITIS",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "RHINITIS",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 12,
              "numAffected": 9,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "SINUSITIS",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 5,
              "numAffected": 4,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 13,
              "numAffected": 7,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "TINEA INFECTION",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "UPPER RESPIRATORY TRACT INFECTION",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 8,
              "numAffected": 5,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "URINARY TRACT INFECTION",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 4,
              "numAffected": 3,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "FALL",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "INFUSION RELATED REACTION",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 12,
              "numAffected": 11,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "SKIN ABRASION",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "SPINAL COMPRESSION FRACTURE",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "ALANINE AMINOTRANSFERASE INCREASED",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "AMYLASE INCREASED",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "ASPARTATE AMINOTRANSFERASE INCREASED",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "LIPASE INCREASED",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 6,
              "numAffected": 4,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "WEIGHT DECREASED",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "DECREASED APPETITE",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "FLUID OVERLOAD",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "HYPERGLYCAEMIA",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 2,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "HYPOKALAEMIA",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "ARTHRALGIA",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 2,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 10,
              "numAffected": 7,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "BACK PAIN",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "BONE PAIN",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 4,
              "numAffected": 3,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "FLANK PAIN",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "GROIN PAIN",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "MUSCLE SPASMS",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 15,
              "numAffected": 8,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "MUSCULAR WEAKNESS",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "MUSCULOSKELETAL CHEST PAIN",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "MYALGIA",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 9,
              "numAffected": 5,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "PAIN IN EXTREMITY",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 5,
              "numAffected": 5,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "SQUAMOUS CELL CARCINOMA",
          "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 4,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "DIZZINESS",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 4,
              "numAffected": 3,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "NEUROPATHY PERIPHERAL",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "PARAESTHESIA",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 4,
              "numAffected": 4,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "PERIPHERAL SENSORY NEUROPATHY",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "POST HERPETIC NEURALGIA",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "TREMOR",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "DEPRESSION",
          "organSystem": "Psychiatric disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "INSOMNIA",
          "organSystem": "Psychiatric disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 5,
              "numAffected": 4,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "HYDRONEPHROSIS",
          "organSystem": "Renal and urinary disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "URINARY RETENTION",
          "organSystem": "Renal and urinary disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "COUGH",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 4,
              "numAffected": 2,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 14,
              "numAffected": 12,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "DYSPNOEA",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 5,
              "numAffected": 5,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "EPISTAXIS",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "NASAL CONGESTION",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 5,
              "numAffected": 4,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "OROPHARYNGEAL PAIN",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "PNEUMONITIS",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "PRODUCTIVE COUGH",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "RHINORRHOEA",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 4,
              "numAffected": 3,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "SINUS CONGESTION",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "ERYTHEMA",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "NIGHT SWEATS",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 4,
              "numAffected": 4,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "PRURITUS",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 6,
              "numAffected": 5,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "RASH",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 8,
              "numAffected": 7,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "RASH MACULO-PAPULAR",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 6,
              "numAffected": 3,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "DEEP VEIN THROMBOSIS",
          "organSystem": "Vascular disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "HYPERTENSION",
          "organSystem": "Vascular disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "DRY EYE",
          "organSystem": "Eye disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "HAEMORRHOIDS",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 6,
              "numAffected": 4,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "MALAISE",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "HYPOGAMMAGLOBULINAEMIA",
          "organSystem": "Immune system disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "ACUTE SINUSITIS",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "CYSTITIS",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "PNEUMONIA",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 5,
              "numAffected": 5,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "DYSURIA",
          "organSystem": "Renal and urinary disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 34
            }
          ]
        },
        {
          "term": "HOT FLUSH",
          "organSystem": "Vascular disorders",
          "sourceVocabulary": "MedDRA 23.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 4
            },
            {
              "groupId": "EG001",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 34
            }
          ]
        }
      ]
    },
    "moreInfoModule": {
      "limitationsAndCaveats": {
        "description": "Enrollment for this study was stopped early as the Sponsor chose not to claim superiority over existing therapies."
      },
      "certainAgreement": {
        "piSponsorEmployee": false,
        "restrictionType": "OTHER",
        "restrictiveAgreement": true,
        "otherDetails": "The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."
      },
      "pointOfContact": {
        "title": "Medical Communications",
        "organization": "Hoffmann-La Roche",
        "email": "genentech@druginfo.com",
        "phone": "800 821-8590"
      }
    }
  },
  "documentSection": {
    "largeDocumentModule": {
      "largeDocs": [
        {
          "typeAbbrev": "Prot_SAP",
          "hasProtocol": true,
          "hasSap": true,
          "hasIcf": false,
          "label": "Study Protocol and Statistical Analysis Plan",
          "date": "2019-10-26",
          "uploadDate": "2021-09-14T09:38",
          "filename": "Prot_SAP_001.pdf",
          "size": 2106700
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2025-10-28",
      "removedCountries": [
        "United Kingdom"
      ]
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D008224",
          "term": "Lymphoma, Follicular"
        }
      ],
      "ancestors": [
        {
          "id": "D008228",
          "term": "Lymphoma, Non-Hodgkin"
        },
        {
          "id": "D008223",
          "term": "Lymphoma"
        },
        {
          "id": "D009370",
          "term": "Neoplasms by Histologic Type"
        },
        {
          "id": "D009369",
          "term": "Neoplasms"
        },
        {
          "id": "D008232",
          "term": "Lymphoproliferative Disorders"
        },
        {
          "id": "D008206",
          "term": "Lymphatic Diseases"
        },
        {
          "id": "D006425",
          "term": "Hemic and Lymphatic Diseases"
        },
        {
          "id": "D007160",
          "term": "Immunoproliferative Disorders"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "C000594389",
          "term": "atezolizumab"
        },
        {
          "id": "D000077269",
          "term": "Lenalidomide"
        },
        {
          "id": "C543332",
          "term": "obinutuzumab"
        }
      ],
      "ancestors": [
        {
          "id": "D010797",
          "term": "Phthalimides"
        },
        {
          "id": "D010795",
          "term": "Phthalic Acids"
        },
        {
          "id": "D000146",
          "term": "Acids, Carbocyclic"
        },
        {
          "id": "D002264",
          "term": "Carboxylic Acids"
        },
        {
          "id": "D009930",
          "term": "Organic Chemicals"
        },
        {
          "id": "D010881",
          "term": "Piperidones"
        },
        {
          "id": "D010880",
          "term": "Piperidines"
        },
        {
          "id": "D006573",
          "term": "Heterocyclic Compounds, 1-Ring"
        },
        {
          "id": "D006571",
          "term": "Heterocyclic Compounds"
        },
        {
          "id": "D054833",
          "term": "Isoindoles"
        },
        {
          "id": "D006574",
          "term": "Heterocyclic Compounds, 2-Ring"
        },
        {
          "id": "D000072471",
          "term": "Heterocyclic Compounds, Fused-Ring"
        }
      ]
    }
  },
  "hasResults": true
}